Jazz Pharmaceuticals reports 19% revenue growth in Q1 2026, with key drug launches and FDA priority review for zanidatamab.

Jazz Pharmaceuticals posted strong Q1 2026 results with total revenues of $1.1 billion, a 19% increase year-over-year, driven by growth in key products like Xywav, Epidiolex, and Zepzelca. The FDA granted Priority Review for zanidatamab in first-line HER2+ gastroesophageal adenocarcinoma, with a PDUFA date set for August 25, 2026, signaling potential new treatment options. The company reaffirmed its 2026 revenue and expense guidance and highlighted ongoing pipeline advancements and business development efforts aimed at long-term growth.